Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation
The purposes of the study are to determine the energy balance and evaluate the nutritional status of patients with ALS, and to investigate the use of NIPPV as respiratory support to treat patients with ALS.
- Trial name
- NCT00116558
- Testing
- Early NIPPV, Standard NIPPV
- Where
- 12 sites in United States
- Volunteers
- 153 people
- Sponsor
- Edward Kasaraskis
Amyotrophic Lateral Sclerosis (ALS)
Safety Study of XT-150 in Participants With ALS
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT06704347
- Testing
- XT-150
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Xalud Therapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS), Motor Neurone Disease (MND)
Metabolism and Nutrition in MND
Motor neurone disease (MND) is a progressive neurological condition that can affect movement, speech, swallowing and breathing. Weight loss and malnutrition are common in people with MND and may be caused by factors including…
- Trial name
- MET-MND (NCT07851714)
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Amyotrophic Lateral Sclerosis
ALS Treatment Extension Study
Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued…
- Trial name
- NCT03136809
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Amyotrophic Lateral Sclerosis
potentiALS - Quality of Life Among Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing and disabling disease with the majority of patients dying 3-5 years after symptom onset.
- Trial name
- potentiALS (NCT06441448)
- Testing
- case focus groups
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- University of Leipzig
Amyotrophic Lateral Sclerosis
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
The purpose of this study is to collect CSF and blood samples that can be used in future research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF) collected in Amyotrophic Lateral Sclerosis (ALS)…
- Trial name
- NCT05116943
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Parkinson's Disease (PD), Alzheimer's Disease (AD)
Quantification of Hsp90 in the Human Brain
This study tests the radiolabeled molecule ("tracer"), [¹¹C]HSP990, using positron emission tomography (PET) imaging to assess whether it can be used to measure levels of Heat Shock Protein 90 (Hsp90).
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT07380204
- Testing
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
ALS
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety and tolerability of RNS60 in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02525471
- Testing
- RNS60
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sabrina Paganoni, M.D.
ALS (Amyotrophic Lateral Sclerosis)
Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)
The purpose of this study is to study use of advance Digital Health Technologies (DHT) and its validity as measures for assessing progression in Amyotrophic Lateral Sclerosis (ALS) patients.
- Trial name
- NCT05276349
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Amyotrophic Lateral Sclerosis
Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis
Specific aims: Aim 1. To determine the incidence of hypoventilation in Amyotrophic Lateral Sclerosis (ALS) patients. Aim 2. To identify the clinical characteristics and risk factors associated . Aim 3.
- Trial name
- NCT00958048
- Testing
- non-invasive ventilation
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Creation of a Clinical Database for the Study of Phenotypic Variability in Motor Neuron Diseases
Study Description: Characterization of Motor Neuron Disease Phenotypes The goal of this observational study is to understand the clinical presentation of motor neuron disease (MND) in patients attending the Neurology Department…
- Trial name
- ALS-PHENO (NCT06318585)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Auxologico Italiano
Amyotrophic Lateral Sclerosis
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also known as COURAGE-ALS)
- Trial name
- NCT05442775
- Testing
- Reldesemtiv
- Where
- 41 sites in United States, Australia and 7 more
- Volunteers
- 71 people
- Sponsor
- Cytokinetics
Motor Neurone Disease, Hypoxemia and/or Hypercapnia
The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease
Patients with Motor Neurone Disease (MND) admitted to Lane Fox Unit /Royal Brompton Hospital and/or reviewed in Lane Fox Unit /Royal Brompton Hospital clinics and/or outreach review will be approached for participation in the…
- Trial name
- NCT03444428
- Testing
- Non Invasive Ventilation, Without Non Invasive Ventilation
- Where
- 2 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Tetraplegia/Tetraparesis, Quadriplegia
Precise Robotically IMplanted Brain-Computer InterfacE
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or…
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
- Trial name
- PRIME (NCT06429735)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Neuralink Corp
Amyotrophic Lateral Sclerosis, ENGRAILED1
Identifying Biomarkers in ALS Patients Using Neuronal Derived Extracellular Vesicles
Rationale. ENGRAILED1 (EN1) is under consideration as a therapeutic approach for amyotrophic lateral sclerosis (ALS). To assess EN1 target engagement in patients, we aim to identify EN1-responsive biomarkers suitable as…
- Trial name
- BALNEV (NCT07334743)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment for ALS.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome, Spinal Muscular Atrophy
- Trial name
- MotorMarker (NCT05663008)
- Testing
- 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
- Where
- Ireland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Amyotrophic Lateral Sclerosis
Salivary Biomarker Discovery by Raman Spectroscopy in ALS (SalivALS)
BACKGROUND/RATIONALE: The paucity of biomarkers for the diagnosis and monitoring of patients affected by Amyotrophic Lateral Sclerosis (ALS) is one of the greatest concerns in ALS clinics and research.
- Trial name
- SalivALS (NCT04233099)
- Testing
- Raman analysis of saliva with data collection and analysis
- Where
- 2 sites in Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Amyotrophic Lateral Sclerosis
ALS Phase II Study of NX210c
This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- SEALS (NCT06365216)
- Testing
- NX210c
- Where
- 16 sites in France
- Volunteers
- 80 people
- Sponsor
- Axoltis Pharma
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease in which motor neuron cells of the brain and spinal cord progressively degenerate and die.
- Trial name
- ALS QoL (NCT07491484)
- Testing
- Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Amyotrophic Lateral Sclerosis Assessment Questionnaire-40
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- TidalHealth, Inc.
Amyotrophic Lateral Sclerosis (ALS)
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
This is a multicenter, open-label, single-arm investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SNUG01 in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- ALS (NCT06645197)
- Testing
- SNUG01
- Where
- 5 sites in China
- Volunteers
- 7 people
- Sponsor
- Peking University Third Hospital